Contact
searchSearch
HMP Global
Login

Meeting Materials

Poster

2757071
A Digital Therapeutic for Treating Major Depressive Disorder: Effectiveness and Safety Results of the MIRAI Randomized Controlled Trial
Abstract: Introduction: Digital therapeutics (DTx) are a new treatment class for major depressive disorder (MDD). This randomized controlled trial evaluated the effectiveness and safety o...
08/20/2024
2758073
A Focus on Functional Recovery in MDD: Patient-Centered Strategies to Address Residual Symptoms and Treatment-Emergent Adverse Effects
A variety of multimodal treatments that can address the spectrum of MDD symptom domains and ongoing management challenges, including residual symptoms and treatment-emergent adverse effec...
08/20/2024
2757093
Attitudes DriVing regional differences in LAI Antipsychotic utilization for schizophrenia among HCPs, patients, and CaregivErs (ADVANCE) Study: Experiences and Perceptions of LAIs from Caregivers
Abstract: Background: Caregivers play an important role in the lives of people with schizophrenia. This analysis aimed to understand the caregivers’ role and gain their perspective toward...
08/20/2024
2757097
Attitudes DriVing regional differences in LAI Antipsychotic utilization for schizophrenia among HCPs, patients, and CaregivErs (ADVANCE) Study: Patients’ Perspectives on Initial and Current Treatments
Abstract: Background: For patients with schizophrenia, long-acting injectable (LAI) antipsychotics can reduce relapse and hospitalization rates and improve adherence versus oral antipsych...
08/20/2024
2757106
AXS-05 (Auvelity) in Major Depressive Disorder: Pooled Data From Two Six-Week Controlled Trials (GEMINI and ASCEND)
Abstract: Introduction: AXS-05 (dextromethorphan-bupropion; Auvelity) is a novel, oral, N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist approved for treating ...
08/20/2024
2732007
Challenges and Approaches for Managing Psychosis in Advanced Parkinson's Disease: A Case Report
Abstract: Parkinson's Disease (PD) psychosis poses major treatment challenges due to the delicate balance required between managing motor deficits and psychotic symptoms. Treating PD asso...
08/20/2024
2757069
Changes in Neuroplasticity Related to Nonpharmacological Interventions for Major Depressive Disorder: A Systematic Literature Review
Abstract: Introduction: People with major depressive disorder (MDD) have impaired neuroplasticity. Antidepressant treatment and some nonpharmacological interventions can lead to changes i...
08/20/2024
2757092
Clinical Effectiveness of Esketamine for Treatment-Resistant Depression: A Real-World Study of Patients in Mindful Health Solutions Clinics
Abstract: BACKGROUND: To generate real-world evidence of esketamine effectiveness for treatment resistant depression (TRD), this study assessed change in depressive symptoms after esketam...
08/20/2024
2732001
Comparative Effectiveness of Oral and Long-acting Injectable Antipsychotics in Schizophrenia: A Real-world Study in the US Medicare Population
Abstract: Objective: Long-acting injectables (LAIs) may provide an advantage over daily oral antipsychotics (OAPs), but little real-world evidence exists in the Medicare population, which...
08/20/2024
2757074
Earlier Use of Long-Acting Injectable Paliperidone Palmitate versus Oral Antipsychotics in Patients With Schizophrenia: An Integrated Patient-Level Post Hoc Analysis of the PRIDE and PROSIPAL studies
Abstract: Objective: A prior integrated patient-level analysis revealed a significant benefit of implementing paliperidone palmitate (PP) versus oral antipsychotics (OAPs) earlier in the ...
08/20/2024
2757103
Effectiveness of Deutetrabenazine for Tardive Dyskinesia When Initiated Using a 4-Week Patient Titration Kit: Final Results of the START Study
Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor for the treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)–related c...
08/20/2024
2732004
Efficacy and safety of iclepertin (BI 425809) in patients with schizophrenia: CONNEX, a Phase III randomized controlled trial program
Abstract: Rationale No effective pharmacological treatments are available for cognitive impairments in schizophrenia. Iclepertin (BI 425809), a glycine transporter-1 inhibitor, enhances N...
08/20/2024
2757109
Enhancing Behavioral Health Workforce: Evaluating the Impact of an HRSA-Funded Interprofessional Training Initiative
Abstract: This research analyzes the outcomes of a federal training grant first awarded in 2017 by the Health Resources and Services Administration (HRSA) to address the shortage of behav...
08/20/2024
2757085
Establishment of a digital therapeutic alliance in patients living with negative symptoms of schizophrenia
Abstract: Introduction: A patient-digital therapeutic (DTx) bond (digital working alliance [DWA]) may be important for DTx success. We assessed whether patients with experiential negative...
08/20/2024
2731999
Evaluation of AXS-05 (dextromethorphan-bupropion) in Major Depressive Disorder Using the Interest-Activity Domain
Abstract: Background: Individuals with major depressive disorder (MDD) with loss of interest and reduced activity respond poorly to serotonergic antidepressants. AXS-05 (dextromethorphan-...
08/20/2024
2757091
Experiences and Perceptions of Psychiatrists Treating Schizophrenia With Long-Acting Injectable Antipsychotics: Qualitative Results From the Multinational ADVANCE Study
Abstract: Background: Psychiatrists’ views on schizophrenia treatment goals and use of long-acting injectable antipsychotics (LAIs) vary widely.
08/20/2024
2757082
Healthcare Resource Utilization Following 6 Months of Treatment With Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia or Bipolar I Disorder
Abstract: Background: The combination of olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. In real...
08/20/2024
2757095
Healthcare Resource Utilization in Patients With Tardive Dyskinesia Treated With Benztropine Compared With a Non-Treated Cohort
Abstract: Background: Benztropine may be prescribed off-label to patients with tardive dyskinesia (TD) to provide symptom relief; however, per benztropine prescribing information, it may ...
08/20/2024
2757087
How Patients with Depression and their Providers Navigate Anhedonia: An Ethnographic Evaluation of Discourse Dynamics of Psychiatrists and Primary Care Providers in Clinical Settings
Abstract: Background Anhedonia, a key symptom of major depressive disorder (MDD), impacts patients' quality of life and treatment outcomes. However, limited research exists on healthcare ...
08/20/2024
2757078
Hybrid Approach to Development of a Patient-Reported Outcomes (PRO) Instrument to Assess the Impact of Tardive Dyskinesia (IMPACT-TD PRO) in Adults
Abstract: Background: Patient-reported outcomes (PROs) are important for assessing disease burden. Specific measures characterizing the multidimensional impact of tardive dyskinesia (TD) ...
08/20/2024
2757083
Impact of Major Depressive Disorder with Prominent Anhedonia on Polypharmacy, Use of Healthcare Services, and Health-related Quality of Life in the United States
Abstract: Background: Despite the prevalence of major depressive disorder (MDD), little is known about the burden of anhedonia, a core MDD symptom associated with MDD severity, functional...
08/20/2024
2732002
Improving Nurse Well-being and Patient Care Quality: Implementing a Mindfulness-Based Stress Reduction Program in an Acute Care Hospital
Abstract: Nurse burnout continues to be a significant challenge in healthcare settings, impacting both the well-being of nurses and the quality of patient care. This presentation introduc...
08/20/2024
2757065
Interim Analysis of a Patient-Reported Impact Measure in the IMPACT-TD Registry
Abstract: Background: The IMPACT-TD Patient Reported Outcome (IMPACT-TD PRO) scale is a newly developed patient questionnaire to assess the multidimensional impact of tardive dyskinesia (...
08/20/2024
2757079
Isolated Hyper-religiosity in Patient after Resection of Sphenoidal Meningioma: A Case Report
Abstract: A 57-year-old female patient with a known history of left frontotemporal meningioma presented to the emergency room with visual and auditory hallucinations and hyper-religiosity...
08/20/2024
2732003
Latent Variable Analysis of Antipsychotic Adherence among South Carolina Medicaid Beneficiaries with Schizophrenia
Abstract: Schizophrenia, a chronic mental illness, requires long-term treatment with antipsychotics, where adherence is crucial for favorable clinical and economic outcomes. Adherence, ho...
08/20/2024
2757100
Long-Term Efficacy of Esketamine Nasal Spray Among Early and Delayed Responders: A Subgroup Analysis of the SUSTAIN-3 Study
Abstract: Objective: To describe the long-term efficacy of esketamine nasal spray (ESK) in adult patients (aged 18-64 years) with treatment-resistant depression (TRD) dosed according to U...
08/20/2024
2757101
Long-Term Safety and Efficacy of Esketamine Nasal Spray by Dosing Frequency in Adults With Treatment-Resistant Depression: Analysis of the SUSTAIN-3 Study
Abstract: Objective: To describe the long-term safety and efficacy of flexibly dosed esketamine nasal spray (ESK) in patients with treatment-resistant depression (TRD) from SUSTAIN-3 (NCT...
08/20/2024
2731996
Lumateperone in the Treatment of Patients With Major Depressive Disorder and Bipolar Disorder With Anxious Distress and Mixed Features
Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder (BD).
08/20/2024
2731997
Lumateperone Treatment for Major Depressive Episodes With Mixed Features in Major Depressive Disorder and Bipolar I or Bipolar II Disorder
Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder (BD). This randomized, ...
08/20/2024
2758480
More than Skin Deep: Examining the Full Impact of Tardive Dyskinesia
Tardive dyskinesia (TD), which affects over 500,000 people in the United States (US), is an involuntary movement disorder associated with dopamine-receptor antagonists–most commonly antip...
08/20/2024
2757081
Multidimensional Impact of Tardive Dyskinesia: Interim Analysis of Clinician-Reported Measures in the IMPACT-TD Registry
Abstract: Background: The IMPACT-TD scale is a newly developed clinical tool to assess the multidimensional impact of tardive dyskinesia (TD) on patients’ quality of life (QoL). Methods: ...
08/20/2024
2731998
Obligate Mirror Alternating Hemi-auto-prosopometamorphopsia of Kith and Kin
Abstract: Introduction: Obligate mirror alternating hemiprosopometamorphopsia has not heretofore been described. Such a case is presented. Methods: Case Report: A 37 year old right hand...
08/20/2024
2757090
Patient-reported depressive symptoms among individuals diagnosed with Major Depressive Disorder with and without prominent anhedonia using a real-world dataset
Abstract: Anhedonia is a core feature of major depressive disorder (MDD). However, little is known about its related symptom burden and its impact on patients’ clinical trajectory. This r...
08/20/2024
2757066
Polypharmacy and deprescribing of cholinesterase inhibitors in dementia: a case report and literature review
Abstract: The patient is an 81-year-old female with a past medical history of dementia who presented to the hospital for a mechanical fall. Her medication reconciliation revealed she had ...
08/20/2024
2757111
Probiotics as an Adjuvant for Microbiota-gut-brain Axis Dysfunction in Depression
Abstract: Depression is a debilitating disorder, and it is expected to overtake cardiac illnesses as the top source of disease burden in 7 years. It is a psychiatric disorder that is diag...
08/20/2024
2757088
Psychiatric Nurse Perceptions of Long-Acting Injectable Therapies for Treating Schizophrenia: Qualitative Results From the Multinational ADVANCE Study
Abstract: Background: Psychiatric nurses play a key role in schizophrenia treatment; their perceptions of long-acting injectable antipsychotics (LAIs) vary. The objectives of the Attitude...
08/20/2024
2758351
Putting it All Together in Bipolar Disorder: Novel Treatment Options Focused on the Whole Patient
Bipolar disorder (BD) is a serious mental illness and a notoriously challenging disease for healthcare professionals to accurately diagnose and manage. As a result, high rates of undertre...
08/20/2024
2732000
Real-World AXS-05 Patient Characteristics in Major Depressive Disorder
Abstract: Introduction: AXS-05 (dextromethorphan-bupropion), a novel, oral, N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, gained approval from the US FDA i...
08/20/2024
2757076
Real-world Change in Depressive Symptoms Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray
Abstract: BACKGROUND: Real-world evidence of clinical benefits of esketamine nasal spray for treatment-resistant depression (TRD) is limited. This study used health insurance claims data ...
08/20/2024
2757098
Real-World Claims Analysis to Characterize the Burden of Tardive Dyskinesia in Long-Term Care Settings
Abstract: Tardive dyskinesia (TD) is a persistent and potentially debilitating movement disorder associated with antipsychotic exposure. Older adults have an increased risk for TD and may...
08/20/2024
2757070
Real-World Safety Profile of Esketamine Nasal Spray During the First 12 Treatment Sessions: An Analysis at 58 Months After Approval in the United States
Abstract: Purpose: To examine real-world incidence of esketamine nasal spray (ESK) treatment-emergent adverse events (TEAEs) of interest (i.e., actively solicited events of sedation, diss...
08/20/2024
2757107
Risk of Relapse among Medicare Advantage Members Diagnosed with Schizophrenia and Receiving Once-monthly Paliperidone Palmitate or First Generation Long-acting Injectable Antipsychotics
Abstract: Assessment of real-world outcomes associated with different antipsychotics helps inform treatment selection for patients with schizophrenia. This real-world study aimed to compa...
08/20/2024
2757104
Safety and Exposure of TV-46000, a Long-Acting Subcutaneous Antipsychotic (LASCA) Formulation of Risperidone, in Adolescent and Young Adult Patients With Schizophrenia: Results From the Phase 3 RISE and SHINE Studies
Abstract: Background: Two phase 3 trials evaluating TV-46000 for schizophrenia enrolled patients aged 13–65 years. Adolescents aged 13–18 years and young adults aged 19–21 years who recei...
08/20/2024
2757108
Sustained Chorea Improvements with Long-Term, Once-Daily Valbenazine in Adults with Huntington’s Disease
Abstract: Background: In the phase 3 KINECT®-HD (NCT04102579) study, valbenazine significantly improved chorea versus placebo in adults with Huntington’s disease (HD). KINECT®-HD2 (NCT044...
08/20/2024
2757096
Switching Patients With Schizophrenia to TV-46000, a Long-Acting Subcutaneous Antipsychotic, From Risperidone Microspheres (R064766): An Exploration of Population Pharmacokinetic-Based Strategies
Abstract: Background: This analysis used pharmacokinetic (PopPK) modeling to characterize dosing conversions and switching strategies from R064766 (a once-every-2-weeks [q2w] intramuscula...
08/20/2024
2758400
Tackling Myths and Misconceptions about Long-Acting Injectables in Schizophrenia
While antipsychotic treatment is essential to achieving and maintaining remission in schizophrenia, conventional antipsychotic treatments are associated with numerous shortcomings, includ...
08/20/2024
2757086
The Junonia Postpartum Depression (PPD) Study: Assessing PPD Care Models in the USA
Abstract: Objective: To describe characteristics of patients from a prospective observational study evaluating postpartum depression (PPD) care pathways. Methods: Junonia is an ongoing ...
08/20/2024
2757068
TMS use in neurological complications following Covid-19 vaccination.
Abstract: Abstract Background Neurological complications after covid-19 are well described. TMS plays a role in the treatment of this condition. However, the use of TMS in neurological co...
08/20/2024
2757072
Treating Major Depressive Disorder After Suboptimal Response to Antidepressant Treatment: Where Do Digital Mental Health Tools Fit in?
Abstract: Introduction: Less than half of patients receiving first-line antidepressant (ADT) treatment for major depressive disorder (MDD) achieve remission. When considering the next tre...
08/20/2024
2757105
Treatment Effect Sizes of Once-Daily Valbenazine for Tardive Dyskinesia and for Chorea Associated with Huntington’s Disease: Post-Hoc Analyses of Two Phase 3 Clinical Trials
Abstract: Once-daily valbenazine is approved for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). Valbenazine effect sizes (Cohen’s d) for th...
08/20/2024
2757075
Treatment Patterns and Persistence Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray
Abstract: BACKGROUND: Durability of esketamine clinical benefits for treatment resistant depression (TRD) may correlate with treatment sessions completed and therapy persistence. Underst...
08/20/2024
2757110
Use of Stellate Ganglion Block for Treatment-Resistant Post-Traumatic Stress Disorder: A Case Report
Abstract: PTSD is defined as a group of symptoms which include intrusive flashbacks and re-experiences of a traumatic event, avoidance of any trauma related stimuli, negative changes in m...
08/20/2024
2757102
Variables Associated with Remission in Patients Treated with Esketamine Nasal Spray or Quetiapine Extended Release: A Post Hoc Subgroup Analysis of the ESCAPE-TRD Study
Abstract: Objective: To examine baseline and disease characteristics of patients with treatment-resistant depression (TRD) who achieved remission at week 8 with quetiapine extended releas...
08/20/2024
2757077
When the treatment for psychogenic polydipsia backfires: the analysis of clozapine-induced neuroleptic malignant syndrome
Abstract: Our case involves a 64-year-old male with a past psychiatric history of schizoaffective disorder (bipolar type; on clozapine 400mg nightly) and who presented to the hospital for...
08/20/2024
2
A Clinical Conundrum: Cardiac Complications with Covid, Covid Vaccines, and Clozapine
Abstract: Background: We and others surmise that clozapine-induced myocarditis may be more common now that Covid-19 virus is among us. Clozapine, Covid, and the mRNA vaccine used to fight...
08/20/2024
8
A Single Arm Pivotal Trial to Assess the Efficacy of AKL-T01, a Novel Digital Intervention Designed to Improve Attention, in Adolescents Diagnosed with Attention Deficit Hyperactive Disorder (ADHD)
Abstract: STARS-ADHD-Adolescents was a multicenter, single-arm trial conducted at 14 US research sites to evaluate objective attention functioning and ADHD symptoms and impairments after ...
08/20/2024
19
Case Report: Adverse Drug Reaction to Montelukast as an Etiology for Recurrent Nightmares
Abstract: Since March of 2020, the leukotriene receptor antagonist Montelukast has been recognized by the FDA to cause adverse neuropsychiatric events including rare cases of nightmares a...
08/20/2024
11
Characteristics and Treatment Patterns in Patients with Unresolved Major Depressive Disorder
Abstract: Objective: To describe key characteristics and treatment patterns in patients with unresolved MDD symptoms by leveraging real-world data. Methods: Patients with unresolved MDD...
08/20/2024
10
Delirium and a History of Alcohol Dependence – What is the Diagnosis?
Abstract: Delirium is not a well-known adverse effect of Vivitrol. This report describes a rare case of delirium involving visual hallucinations and grandiose delusions associated with Vi...
08/20/2024
28
Differences in Patient and Healthcare Professional Perspectives on the Key Impacts of Tardive Dyskinesia
Abstract: Background: Physical manifestations of tardive dyskinesia (TD) impact daily activities and present a substantial psychosocial burden.
08/20/2024
29
Dosing and Treatment Patterns of Deutetrabenazine When Initiated Using a 4-Week Patient Titration Kit: Interim Results of the START Study
Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor (VMAT2i) for treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)-rela...
08/20/2024
20
Drug-Drug Interactions With Vesicular Monoamine Transporter 2 Inhibitors: Population Estimate of Patients With Tardive Dyskinesia at Risk in Real-World Clinical Practice
Abstract: Background: Valbenazine and deutetrabenazine (vesicular monoamine transporter 2 inhibitors) are approved in the US for treatment of adults with tardive dyskinesia (TD). Valbenaz...
08/20/2024
23
Education to Improve Treatment-Resistant Depression Diagnosis in the Outpatient Behavioral Health Setting
Abstract: Treatment-resistant depression can be difficult to identify in the outpatient behavioral health setting due to a lack of clear diagnostic guidelines. The evidence-based improvem...
08/20/2024
18
EEG Topography and LORETA Tomography in Neuropathology and Treatment of Genetic Epilepsy
Abstract: Two patients with previous unsuccessful psychiatric treatment under went a neurophysiologic evaluation method that included EEG, QEEG and Loreta brain scans. Each patient's lab ...
08/20/2024
33
Fentanyl in Focus: Perspectives on Polysubstance Use in 2022
Abstract: Fentanyl positivity grew by nearly 150% nationally from 2019 to 2022 and is now the most frequently detected drug in those analyzed with substance use disorder. Furthermore, a r...
08/20/2024
3
Global Improvements and Psychiatric Stability in Adults with Tardive Dyskinesia and Mood Disorder: Post Hoc Analyses of Two Long-Term Valbenazine Studies
Abstract: Background: Effective and comprehensive treatment of tardive dyskinesia (TD) requires reducing patients’ abnormal involuntary movements while maintaining their psychiatric stabi...
08/20/2024
26
Health Disparities among Patients with Schizophrenia in an Integrated Healthcare System
Abstract: Background: The substantial disease burden of schizophrenia may be accompanied by disparities in diagnosis and treatment, such as with the use of second-generation antipsychotic...
08/20/2024
5
Impact of Clinician and Practice Characteristics on Utilization of and Attitudes Toward Long-Acting Injectable Antipsychotics in Schizophrenia: A Survey of US-Practicing Psychiatric Clinicians (DECIDE)
Abstract: Background: Social determinants of health (eg, race/ethnicity, resources) impact quality of care for a number of chronic diseases. Methods: In DECIDE, US-based psychiatric clin...
08/20/2024
15
Long-term Safety, Tolerability, and Effectiveness of TV-46000—a Long-Acting Subcutaneous Antipsychotic (LASCA)—in Patients With Schizophrenia: A Phase 3, Randomized, Double-Blind Study (SHINE)
Abstract: Background: TV-46000 is a long-acting subcutaneous antipsychotic (LASCA) that combines risperidone and an innovative, copolymer-based drug delivery technology. In the RISE study...
08/20/2024
12
Matching-adjusted Indirect Treatment Comparison and Network Meta-Analysis of Zuranolone to Standard-of-care Antidepressant Therapies for the Acute Treatment of Adults with Major Depressive Disorder
Abstract: Background: Major depressive disorder (MDD) is a debilitating disease for which there is an unmet need for rapid-acting treatments. Zuranolone is an investigational oral, once-d...
08/20/2024
27
Medication Adherence and Healthcare Resource Utilization in South Carolina Medicaid Beneficiaries with Schizophrenia or Schizoaffective Disorder: Long-acting Injectable vs. Oral Antipsychotics
Abstract: Background: Schizophrenia requires long-term treatment with antipsychotics; however, poor adherence to antipsychotic treatment can result in increased healthcare resource utiliz...
08/20/2024
32
Patient Outcomes Post Hospitalization Discharge Among Patients With Schizophrenia Treated With a Long Acting Injectable or Switched to a New Oral Antipsychotic Medication
Abstract: Background: Low adherence to antipsychotic medication following a hospital discharge among patients with schizophrenia can lead to a higher risk of relapse and greater health ca...
08/20/2024
21
Patient Satisfaction With the Deutetrabenazine 4-week Patient Titration Kit: Interim Results of the
START Study
Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor (VMAT2i) for treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)-rela...
08/20/2024
22
Patients With Tardive Dyskinesia at Risk for Drug-Drug Interactions With Vesicular Monoamine Transporter 2 Inhibitors Across Age Groups, Underlying Psychiatric Conditions, and Payer Types
Abstract: Background: Valbenazine and deutetrabenazine (vesicular monoamine transporter 2 inhibitors) are indicated for treatment of adults with tardive dyskinesia (TD). Valbenazine label...
08/20/2024
6
Preferences for Selecting and Initiating Long-Acting Injectable Antipsychotics: A Survey of US Psychiatric Clinicians (Results from the DECIDE Survey)
Abstract: Background: Although long-acting injectable antipsychotics (LAIs) improve adherence and reduce schizophrenia relapse rates, they remain underutilized in clinical practice. Meth...
08/20/2024
30
Real World Effectiveness of Deutetrabenazine When Initiated Using a 4-Week Patient Titration Kit: Interim Results of the START Study
Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor (VMAT2i) for treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)-rela...
08/20/2024
14
Real-world assessment of treatment inertia in the management of patients treated for major depressive disorder in the US
Abstract: Background: Major depressive disorder (MDD) is a debilitating illness in which depressive symptoms may persist after antidepressant treatment. APA guidelines recommend clinician...
08/20/2024
24
Real-World Use of Esketamine Nasal Spray at 46 Months: Characterizing Healthcare Settings, Prescribers, Pharmacies, Patients, and Key Safety Data
Abstract: Background: Upon approving esketamine nasal spray (ESK) in conjunction with an oral antidepressant for treatment-resistant depression in adults, the FDA required a Risk Evaluati...
08/20/2024
25
Sustained Response to Esketamine Nasal Spray in Patients With Treatment-Resistant Depression: Analysis of Long-Term Data from the SUSTAIN-2 Study
Abstract: Background: This post hoc analysis of SUSTAIN-2 (NCT02497287), an open-label, long-term safety and efficacy study of esketamine nasal spray (ESK), assessed sustained response (S...
08/20/2024
31
The Efficacy and Safety of Esketamine Nasal Spray Versus Quetiapine Extended Release Over 32 Weeks in Patients With Treatment-Resistant Depression: A Subgroup Analysis of the ESCAPE-TRD Study
Abstract: Objective: ESCAPE‑TRD (NCT04338321), a randomized, open-label, rater-blinded, trial demonstrated benefits for esketamine nasal spray (ESK) versus quetiapine extended release (QX...
08/20/2024
16
The SOLARIS Protocol: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Assessing Safety and Efficacy of TV-44749 (Olanzapine for Extended-Release Injectable Suspension Use) in Adults With Schizophrenia
Abstract: Background: Among patients with schizophrenia, nonadherence to oral antipsychotics increases relapse risk. Adherence may be improved with long-acting injectable (LAI) antipsycho...
08/20/2024
1
Total Cost of Care Following First-Line Antidepressant Treatment Failure Among Patients With Major Depressive Disorder in the United States
Abstract: OBJECTIVES: To evaluate total all-cause healthcare costs among US patients diagnosed with major depressive disorder (MDD) who failed first-line antidepressant treatment (ADT). ...
08/20/2024
7
Transitioning Patients to Long-Acting Injectable Antipsychotics: Attitudes and Perceptions of US Clinicians Based on a Hypothetical Case (Results from the DECIDE Survey)
Abstract: Background: Treatment with long-acting injectable antipsychotics (LAIs) reduces relapses in schizophrenia; however, best practices for introducing and transitioning patients to ...
08/20/2024
17
TV-46000—a Long-Acting Subcutaneous Antipsychotic (LASCA) for the Treatment of Schizophrenia: Local Tolerability and Injection Site Reactions
Abstract: Background: The phase 3 schizophrenia program for TV-46000, a long-acting subcutaneous antipsychotic (LASCA) formulation of risperidone, included the RISE efficacy study (NCT035...
08/20/2024
13
Using the Ketogenic Diet as an Intervention to Treat Chronic Mental Disorders
Abstract: Background: In 2020, approximately 14.2 million US adults suffered with serious mental illness. Despite advances in pharmacological treatments, chronic psychiatric disorders rem...
08/20/2024
4
Valbenazine Improves Tardive Dyskinesia With or Without Concomitant Antipsychotic Therapy: A Meta-Analysis of Three Long-Term Valbenazine Trials
Abstract: Background: Valbenazine is a highly selective vesicular monoamine transporter 2 inhibitor indicated for tardive dyskinesia (TD), a persistent and potentially debilitating moveme...
08/20/2024
9
Willingness-to-Pay Analysis of Zuranolone in Major Depressive Disorder: a US Societal Perspective
Abstract: OBJECTIVES: Evaluate clinical and economic outcomes of zuranolone, an investigational drug, versus standard-of-care (SOC) antidepressants in adult patients with major depressive...
08/20/2024
1
(#1) Clinician Perspectives on the Efficacy and Safety/Tolerability of Olanzapine Compared With Other Antipsychotics: Results From the SONAR (Survey on Olanzapine Needs and Attitudes Research) Study
Abstract: Olanzapine is a second-generation antipsychotic with a well-established efficacy:safety profile. Since olanzapineís approval in 1996 for treatment of schizophrenia, more antipsy...
07/10/2025
10
(#10) Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From an Additional Randomized, Double-Blind, Phase 3 Trial
Abstract: Background: Lumateperone is FDA-approved to treat schizophrenia and bipolar depression. This Phase 3, randomized, double-blind, placebo-controlled, multicenter trial (NCT0506170...
07/10/2025
11
(#11) Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress
Abstract: Background: Lumateperone is FDA-approved to treat schizophrenia and depressive episodes associated with bipolar I or II disorder.
07/10/2025
12
(#12) Change in Clinician-Rated and Patient-Reported Depression Severity After Esketamine Nasal Spray as Monotherapy in Adult Patients With Treatment-Resistant Depression: A Post Hoc Analysis of Item Scores
Abstract: Objective: To evaluate improvements in items of the Montgomery-≈sberg Depression Rating Scale (MADRS) and Patient Health Questionnaire-9 (PHQ-9) over 4 weeks of esketamine nasal...
07/10/2025
13
(#13) CT-152, a Prescription Digital Therapeutic for Major Depressive Disorder: A Real-World Analysis of Durability of Treatment Effect
Abstract: Introduction: CT-152 is a prescription digital therapeutic for treating patients with major depressive disorder (MDD) as an adjunct to antidepressant medication. The durability ...
07/10/2025
14
(#14) Efficacy of CT-152 for Major Depressive Disorder Using the Self-Reported 9-Item Patient Health Questionnaire in Participants With Baseline Anxiety Symptoms and/or Difficulty Sleeping
Abstract: Introduction: CT-152 is a prescription digital therapeutic adjunct to antidepressant medication for patients with major depressive disorder (MDD) that has shown benefit over sha...
07/10/2025
15
(#15) Responders and Participant-Reported Depressive Symptom Clusters That may Benefit From CT-152 Therapy for Major Depressive Disorder
Abstract: Introduction: CT-152 is a prescription digital therapeutic adjunct to antidepressant medication for patients with major depressive disorder (MDD). In the Mirai trial (NCT0477028...
07/10/2025
16
(#16) Symptoms of Major Depressive Disorder That Potentially Benefit From the Digital Therapeutic CT-152
Abstract: Introduction: CT-152 is a prescription digital therapeutic adjunct to antidepressant medication for patients with major depressive disorder (MDD). This post hoc analysis of the ...
07/10/2025
17
(#17) Early Dose Management and Up-Titration of Esketamine to 84 mg in the Double-Blind Induction Phase of the Randomized, Active-Controlled, Phase 3 TRANSFORM-2 Study
Abstract: Background: The Phase 3 TRANSFORM-2 study (NCT02418585/Popova et al.Am J Psychiatry.2019;176[6]:428-438) evaluated the efficacy and safety of esketamine nasal spray and supporte...
07/10/2025
18
(#18) Efficacy and Safety of a Single Administration of the N-methyl-D-aspartate Subunit 2B-Selective Negative Allosteric Modulator, BI 1569912, in People Living with Major Depressive Disorder: A Phase Ib Randomized Controlled Trial
Abstract: Background: BI 1569912 is a selective negative allosteric modulator of NR2B subunit-containing NMDA receptors (NR2B NAM) in development for major depressive disorder (MDD). Me...
07/10/2025
19
(#19) Efficacy and Safety of Esketamine Nasal Spray as Monotherapy in Adult Patients with Treatment-Resistant Depression for up to 4-Months of Treatment: A Post Hoc Analysis
Abstract: Objective: To evaluate the efficacy and safety of esketamine nasal spray (ESK) monotherapy in adults with treatment-resistant depression (TRD) from a multicenter study (NCT04599...
07/10/2025
2
(#2) d-Amphetamine Transdermal System in Treatment of Children and Adolescents With ADHD: ADHD-RS-IV Score Analysis From a Pivotal Trial
Abstract: Background: In a pivotal study, the dextroamphetamine transdermal system (d-ATS) met primary and secondary efficacy endpoints for ADHD in children and adolescents. d-ATS efficac...
07/10/2025
20
(#20) Empowering Patients as Educators: Transforming Patient Questions and Insights into Enhanced Clinical Knowledge and Practice
Abstract: Goal: This project investigates how patients undergoing active treatment with a novel FDA-approved antidepressant, esketamine for treatment-resistant depression, can meaningfull...
07/10/2025
21
(#21) Esketamine Following Failure of Transcranial Magnetic Stimulation in Patients with Treatment Resistant Depression
Abstract: Major depressive disorder is the leading cause of disability worldwide. Almost a third of patients with major depression failed to achieve remission despite treatment with multi...
07/10/2025
22
(#22) Initiating dextromethorphan 45 mg-bupropion 105 mg (AXS-05) in Patients with Major Depressive Disorder (MDD): Expert Panel Consensus Recommendations
Abstract: Background: In the treatment of MDD, critical needs remain for improved patient outcomes through medications with novel mechanisms of action (MOA). Dextromethorphan 45 mg-buprop...
07/10/2025
23
(#23) Long-Term Adjunctive Lumateperone Treatment in Major Depressive Disorder: Results From a Six-Month Open-Label Extension Study
Abstract: Background:Lumateperone is FDA-approved to treat schizophrenia and bipolar depression. Adjunctive lumateperone 42mg efficacy and safety was demonstrated in patients with major d...
07/10/2025
24
(#24) Long-Term Safety and Efficacy of Esketamine Nasal Spray as Monotherapy: A Post Hoc Analysis of the SUSTAIN-3 Study
Abstract: Introduction: Esketamine nasal spray (ESK) is approved for treatment of adults with treatment-resistant depression as monotherapy or with an oral antidepressant (OAD). SUSTAIN-3...
07/10/2025
25
(#25) Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial
Abstract: Background: Lumateperone is FDA-approved to treat schizophrenia and bipolar depression. This Phase 3, randomized, double-blind, placebo-controlled, multicenter trial (NCT0498594...
07/10/2025
26
(#26) Real-World Experience with Treatment and Expectations by Satisfaction Status of Persons with Major Depressive Disorder
Abstract: People treated for Major Depressive Disorder (MDD) exhibit varying levels of satisfaction and differing expectations regarding their MDD treatments. This study examines the rela...
07/10/2025
27
(#27) A Rare Case of Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT) Presenting with Stroke-like Symptoms
Abstract: Lithium is a lifesaving medication and the gold standard for management of bipolar disorder. It has a narrow therapeutic index, making toxicity an important clinical concern. Th...
07/10/2025
28
(#28) A Qualitative, Interview-based Study of Patient, Caregiver, And Prescriber Rankings of Functional Outcome Improvements in Schizophrenia
Abstract: Functional impairment in schizophrenia results in substantial burden to patients, caregivers, and healthcare systems. Addressing this impairment remains a critical unmet need in...
07/10/2025
29
(#29) Advancing Schizophrenia Treatment: A Modified Delphi Consensus on The Critical Role of Psychiatric Pharmacists in Prescription Digital Therapeutics
Abstract: Background: Prescription digital therapeutics (PDTs) are software-based interventions for managing and treating medical conditions prescribed by healthcare providers and dispens...
07/10/2025
3
(#3) Effect of Centanafadine on the AIM-A After 6 Weeks of Treatment in Adults with ADHD: A Pooled Analysis of Two Phase 3 Trials
Abstract: Objective: ADHD is a chronic and prevalent neurodevelopmental disorder in adults, characterized by symptoms of inattention, hyperactivity, and impulsivity. This pooled analysis ...
07/10/2025
30
(#30) Association of Antipsychotic Medication Nonadherence With All-Cause Mortality in Newly Treated Adults With Schizophrenia: A Retrospective Healthcare Claims Study
Abstract: Background: Clinical data support an association between antipsychotic nonadherence and adverse outcomes in schizophrenia; however, the influence of nonadherence on mortality re...
07/10/2025
31
(#31) Baseline Severity of Illness and Response to Treatment With Aripiprazole Lauroxil Every 2 Months: A Post Hoc Analysis of Phase 3 ALPINE Clinical Trial Data
Abstract: OBJECTIVE: This post hoc analysis examined the efficacy and safety of aripiprazole lauroxil (AL) every-2-months for the treatment of schizophrenia by baseline severity of illnes...
07/10/2025
32
(#32) Clozapine Toxicity in Real-World Practice: The Critical Role of Rapid Therapeutic Drug Monitoring
Abstract: Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, but it requires careful monitoring due to its narrow therapeutic index and potential for lif...
07/10/2025
33
(#33) Earlier Use of Long-Acting Injectable Paliperidone Palmitate versus Oral Antipsychotics in Patients With Schizophrenia: A Post-hoc Analysis From PROSIPAL
Abstract: Objective: The analysis evaluated outcomes following initiation of paliperidone palmitate 1-month (PP1M) vs oral antipsychotics (OAPs) within ?3-years and >3-5-years of a sch...
07/10/2025
34
(#34) Efficacy of Olanzapine Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use Demonstrated in Patients With Schizophrenia: Results From a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial (SOLARIS)
Abstract: TV-44749 is a once-monthly, subcutaneous, extended-release injectable based on innovative copolymer delivery technology that ensures controlled release of olanzapine, designed t...
07/10/2025
35
(#35) Enabling Conversations About Long-Acting Injectable Antipsychotics Among HCPs, Patients, and Caregivers With the Long-Acting Injectables: Conversations and Resources for Education (LAI-CARE) Website
Abstract: Background: For people with schizophrenia, long-acting injectable antipsychotics (LAIs) can improve adherence and clinical outcomes versus oral antipsychotics, yet remain underu...
07/10/2025
36
(#36) Engagement, Effectiveness, and Patient Experience of an Investigational Digital Therapeutic for Experiential Negative Symptoms of Schizophrenia: An Exploratory Study
Abstract: Background: CT-155/BI 3972080 is an investigational digital therapeutic for treatment of experiential negative symptoms (ENS) of schizophrenia. Methods: This multicenter, 7-wee...
07/10/2025
37
(#37) Exploration of Negative Symptoms and Digital Application Use in People with Schizophrenia
Abstract: Background: Negative symptoms of schizophrenia (NS) profoundly impact functional outcomes. As there are currently no approved pharmacotherapies for NS, innovative treatments are...
07/10/2025
38
(#38) Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Bipolar I Disorder
Abstract: OBJECTIVE: Combination olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. OLZ/SAM treatme...
07/10/2025
39
(#39) Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia
Abstract: OBJECTIVE: Combination olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. OLZ/SAM treatme...
07/10/2025
4
(#4) Impact of Centanafadine on Executive Functioning in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder: Analysis of Conners 3 and Exit Survey Responses
Abstract: Objective: To compare the executive functioning (EF) efficacy measure with patient exit interviews in a pediatric population treated with centanafadine (CTN), a norepinephrine, ...
07/10/2025
40
(#40) How Same-Day Clozapine Levels can Improve Nonadherence Detection and Guide Treatment Strategies
Abstract: Antipsychotic nonadherence increases the risk of relapse, rehospitalization, and adverse outcomes for patients. Monitoring medication adherence is challenging because patient se...
07/10/2025
41
(#41) Long-acting Injectable Treatments for Schizophrenia: Differences in Attitudes and Preferences Among Healthcare Professionals and Patients From the SOLARIS Trial Experiences Study
Abstract: TV-44749 is an innovative, once-monthly, subcutaneous (SC) long-acting injectable (LAI) olanzapine. TV-44749 is designed to provide sustained efficacy without oral supplementati...
07/10/2025
42
(#42) Real-World Treatment Patterns of Patients With Schizophrenia Using Oral Olanzapine and the Associated Impact of Non-adherence on Healthcare Resource Utilization
Abstract: Non-adherence to oral antipsychotics is a barrier to optimal outcomes for patients with schizophrenia. This study aimed to identify treatment patterns and the impact of treatmen...
07/10/2025
43
(#43) Use Of Machine Learning to Identify Variations in Clinical Characteristics, Healthcare Resource Utilization, and Treatment Adherence Among Patients With Schizophrenia Initiating Oral Olanzapine Treatment
Abstract: Oral antipsychotic treatments are associated with poor adherence and high disease/healthcare resource utilization (HCRU) burden in patients with schizophrenia. Long-acting injec...
07/10/2025
44
(#44) Longitudinal Real-World Study of the Patient Journey of a National Sample of Beneficiaries with Schizophrenia Dually Eligible for Medicare & Medicaid
Abstract: Introduction: Almost half of US patients with schizophrenia are dual eligibles; however, there is limited understanding of their journey in terms of receipt of long-acting injec...
07/10/2025
45
(#45) Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use Is Designed for Sustained Efficacy and to Eliminate the Risk of Post-injection Delirium/Sedation Syndrome: In Vitro and Clinical Data
Abstract: Use of intramuscular (IM) long-acting injectable (LAI) olanzapine is limited due to a boxed warning for post-injection delirium/sedation syndrome (PDSS) and the associated Risk ...
07/10/2025
46
(#46) Perspectives of Psychiatrists and Psychiatric Nonphysicians on Treating Schizophrenia With Long-Acting Injectable Antipsychotics: Subgroup Analysis From the Multinational ADVANCE Study
Abstract: Background: Long-acting injectable antipsychotics (LAIs) improve adherence and reduce relapse compared with oral antipsychotics, but LAI use varies. This analysis of the Attitud...
07/10/2025
47
(#47) Real-World Clinical Outcomes Among Patients Receiving the Long-Acting Injectable Antipsychotic TV-46000 Versus Second-Generation Oral Antipsychotics
Abstract: Background: TV-46000 is a long-acting subcutaneous injectable form of risperidone for the treatment of schizophrenia in adults.
07/10/2025
48
(#48) Treatment Patterns and Healthcare Resource Utilization Among Patients Receiving the Long-Acting Injectable Antipsychotic TV-46000 Versus Second-Generation Oral Antipsychotics
Abstract: Background: Long-acting injectable antipsychotics (LAIs) have been associated with improved adherence and outcomes when compared with oral antipsychotics (OAs).
07/10/2025
49
(#49) Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: A Patient Subgroup Analysis of a 4-Year Open-Label Study
Abstract: Objective: To analyze subgroup data from a 4-year, open-label study of combined olanzapine and samidorphan (OLZ/SAM) in adults with schizophrenia, schizophreniform disorder, or ...
07/10/2025
5
(#5) Effect of External Heat Application on the Pharmacokinetics of d-Amphetamine Transdermal System and Comparison of Pharmacokinetics of d-Amphetamine Transdermal System With Oral Formulations
Abstract: Background: d-Amphetamine transdermal system (d-ATS) is a transdermal dextroamphetamine formulation approved for treating ADHD patients aged ?6 years. This study evaluates the e...
07/10/2025
50
(#50) Schizoaffective Disorder Complicated by Prolonged Childhood Khat Use: A Case Report
Abstract: This is a case involving a 23-year-old male patient with a history of heavy khat use in early childhood, who was diagnosed with bipolar type schizoaffective disorder at the age ...
07/10/2025
51
(#51) Social Determinants of Health among Patients with Experiential Negative Symptoms Living with Schizophrenia: Medical Expenditure Panel Survey
Abstract: Introduction: Experiential negative symptoms (ENS) of schizophrenia include avolition, asociality, and anhedonia, which impact quality of life and functioning. This study assess...
07/10/2025
52
(#52) Estimation of the Minimal Clinically Important Difference (MCID) and Longitudinal Change in the Tardive Dyskinesia Impact Scale (TDIS), a Validated, Tardive Dyskinesia-Specific, Patient-Reported Outcome Measure
Abstract: Tardive Dyskinesia Impact Scale (TDIS) evaluates TD symptom impact over the previous 7 days and was a KINECTÆ3, KINECTÆ4, and KINECT-PRO outcome. Objectives were to estimate min...
07/10/2025
53
(#53) Clinical and Demographic Characteristics of Patients Taking Antipsychotics and Treatment Patterns Among Patients With Tardive Dyskinesia in a Long-Term Care Setting
Abstract: Background: This study described the clinical/demographic characteristics of patients taking antipsychotics/metoclopramide in a long-term care (LTC) setting and treatment patter...
07/10/2025
54
(#54) Multidimensional Impact of Tardive Dyskinesia Reported by Clinicians: Second Interim Analysis From the IMPACT-TD Registry
Abstract: Background: We previously assessed the multidimensional impact of tardive dyskinesia (TD) on an initial population of individuals (n=286) in the IMPACT-TD Registry. Here, we rep...
07/10/2025
55
(#55) Multidimensional Impact of Tardive Dyskinesia: Second Interim Analysis of a Patient-Reported IMPACT Measure in the IMPACT-TD Registry
Abstract: Background: We previously assessed patient-reported multidimensional impact of tardive dyskinesia (TD) on an initial set of participants (n=286) in the IMPACT-TD Registry. Here,...
07/10/2025
56
(#56) Real-World Evidence of Patient Experience With Once-Daily Deutetrabenazine Extended-Release Tablets for the Treatment of Tardive Dyskinesia in the United States
Abstract: Background: Deutetrabenazine is approved by the Food and Drug Administration for treatment of tardive dyskinesia (TD) and chorea in Huntington disease (HD). This study aimed to ...
07/10/2025
57
(#57) Remission of Tardive Dyskinesia in Patients Receiving Long-Term Valbenazine Treatment
Abstract: Once-daily valbenazine is approved for tardive dyskinesia (TD) and chorea associated with Huntingtonís disease. In a 48-week open-label study (KINECTÆ 4 [NCT02405091]), treatmen...
07/10/2025
58
(#58) Valbenazine Improves the Impacts and Symptoms of Tardive Dyskinesia: Topline Results from the Phase 4 KINECT-PRO Study
Abstract: Once-daily valbenazine is approved for tardive dyskinesia (TD) and Huntingtonís chorea. KINECT-PRO is the first study to report the effects of an approved TD medication on the i...
07/10/2025
59
(#59) A Literature Review of SSRI-Induced Akathisia and its Potential Role in Suicidality
Abstract: Objectives: This review aims to provide an overview of SSRI-induced akathisia, examining its prevalence, underlying mechanisms, and potential role in increasing suicidality. Me...
07/10/2025
6
(#6) ADHD and Comorbid Diagnosis: Considerations of Prevalence In Clinical Settings Using Bayesian Statistics
Abstract: This presentation explores the rates of ADHD being diagnosed, suggesting potential underdiagnosis, particularly in patients presenting with anxiety and depression. These co-occu...
07/10/2025
60
(#60) Clenched Secrets: The Hidden Side Effects of Psychiatric Meds
Abstract: Bruxism, a debilitating condition characterized by involuntary teeth grinding, has been increasingly linked to pharmacological treatments, though the underlying mechanisms remai...
07/10/2025
61
(#61) The Point of No Return? Cannabis Addiction and Lasting Psychosis
Abstract: This case examines a 23-year-old male whose cannabis addiction precipitated treatment-resistant psychosis. After one year of heavy use, he developed paranoid delusions (e.g., be...
07/10/2025
63
(#63) ìThe Pregnancy Test is Lying:" A Case Report on a Four-Year Battle of Undiagnosed Delusion of Pregnancy
Abstract: Both pseudocyesis and delusion of pregnancy are so rare that most information on them is found within case reports. Considering the similar presentation and risk factors of both...
07/10/2025
64
(#64) Patient Preferences of Sodium Oxybate Treatment for Narcolepsy: RESTORE End-of-Study Survey Data
Abstract: Introduction: Immediate-release (IR) oxybates require patients to awaken 2.5 to 4 hours after their first dose for a second dose. Once-nightly sodium oxybate (ON-SXB) is an exte...
07/10/2025
65
(#65) AI Scribes in Psychiatric Mental Health: Emerging Research and the Future of Augmented Clinical Practice
Abstract: Burnout among psychiatric clinicians continues to rise due to excessive documentation, administrative demands, and limited time for direct patient care. This project explores ho...
07/10/2025
66
(#66) Mitigating Burnout in Acute Care Nurses: The Role of MBSR Program
Abstract: Burnout among nurses remains a huge problem in the healthcare setting, especially within acute care hospital settings, where long hours, high emotional demands, and complex resp...
07/10/2025
7
(#7) Connecting With The Young Patient Through Media: Children TV Shows That Portray Mental Disorders
Abstract: Background: It is essential for psychiatrists to build rapport with their patients by engaging in meaningful conversation. However, children with mental health conditions are of...
07/10/2025
8
(#8) Project C.C.R.I.S.I.S.: Community-based Crisis Response Intervention Strategies for Interdisciplinary Standardization
Abstract: nurses can be influential leaders working to improve access to care for the over 3.5 million children and adolescents in the United States who need psychiatric care but struggle...
07/10/2025
9
(#9) Efficacy and Safety of AXS-05 in Alzheimer's Disease Agitation: A Phase 3 Randomized-Withdrawal Double-Blind Placebo-Controlled Study
Abstract: Approximately 70% of individuals with Alzheimerís disease (AD) experience agitation. Current pharmacologic therapies are limited and additional treatments are needed. AXS-05 (de...
07/10/2025
68
LAI360 Learning Lab: Raising the Bar on Schizophrenia Outcomes: Optimizing the Role of Long-Acting Injectable Antipsychotics
While antipsychotic treatment is essential to achieving and maintaining remission in schizophrenia, conventional antipsychotic treatments are associated with numerous shortcomings, includ...
07/10/2025
67
Navigating the Spectrum of Bipolar Disorder: New Options with Novel Mechanisms of Action
Bipolar disorder (BD) is a serious mental illness and a notoriously challenging disease for healthcare professionals to accurately diagnose and manage. As a result, high rates of undertre...
07/10/2025
69
TD360 Learning Lab: Facing the Impact of Tardive Dyskinesia
Tardive dyskinesia (TD), which affects over 500,000 people in the United States (US), is an involuntary movement disorder associated with dopamine-receptor antagonistsñmost commonly antip...
07/10/2025

Psych Congress Elevate

May 28-31, 2025
Las Vegas, NV

Addressing the needs of early-career and forward-thinking mental health professionals through dynamic psychopharmacology and future-focused education combined with unique opportunities to find a mentor and network with faculty and peers.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use